Title:
ANTIBODY BINDING CTLA-4 AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/222961
Kind Code:
A1
Abstract:
Provided are a method for depleting regulatory T cells (Tregs) and/or increasing the proportion of CD8+ T cells/Tregs in a subject, a method for treating a refractory cancer in a subject, a combination therapy for treating a cancer, a method for reducing side effects of treating a cancer using a CTLA4 antibody, a method for implementing long-term administration or administration when necessary for a cancer patient, an administration method for an anti-CTLA-4 single heavy chain antibody, a unit dose composition, the use of an anti-CTLA-4 single heavy chain antibody in preparation of a drug, a method for determining the administration dose of an anti-tumor drug, and a method for determining the administration form of an anti-tumor drug.
Inventors:
GAN XIN (CN)
XIANG JINFENG (CN)
TAO XIAOLU (CN)
JI JINFENG (CN)
CHEN XIAOXIANG (CN)
XIANG JINFENG (CN)
TAO XIAOLU (CN)
JI JINFENG (CN)
CHEN XIAOXIANG (CN)
Application Number:
PCT/CN2022/087922
Publication Date:
October 27, 2022
Filing Date:
April 20, 2022
Export Citation:
Assignee:
HARBOUR BIOMED SHANGHAI CO LTD (CN)
International Classes:
C07K16/28; A61K39/395; A61P35/00
Domestic Patent References:
| WO2020185722A2 | 2020-09-17 |
Foreign References:
| CN111655728A | 2020-09-11 | |||
| CN110655579A | 2020-01-07 | |||
| US20150283234A1 | 2015-10-08 |
Other References:
PAI CHIEN-CHUN STEVEN, SIMONS DONALD M., LU XIAOQING, EVANS MICHAEL, WEI JUNNIAN, WANG YUNG-HUA, CHEN MINGYI, HUANG JOHN, PARK CHA: "Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 129, no. 1, 2 January 2019 (2019-01-02), GB , pages 349 - 363, XP055978383, ISSN: 0021-9738, DOI: 10.1172/JCI123391
LI JIAN;YAN FANG;YANG JINBO;WANG YUZHU: "Application of model-informed drug development approach in dose optimization: Insights from the modification of nivolumab dosage regimen", CHINESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 25, no. 4, 26 April 2020 (2020-04-26), pages 408 - 412, XP055978385, ISSN: 1009-2501, DOI: 10.12092/j.issn.1009-2501.2020.04.009
LI JIAN;YAN FANG;YANG JINBO;WANG YUZHU: "Application of model-informed drug development approach in dose optimization: Insights from the modification of nivolumab dosage regimen", CHINESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 25, no. 4, 26 April 2020 (2020-04-26), pages 408 - 412, XP055978385, ISSN: 1009-2501, DOI: 10.12092/j.issn.1009-2501.2020.04.009
Attorney, Agent or Firm:
LIU, SHEN & ASSOCIATES (CN)
Download PDF:
Previous Patent: FXIA INHIBITOR AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USE THEREOF
Next Patent: LAYERED CATALYTIC ARTICLE
Next Patent: LAYERED CATALYTIC ARTICLE